Sun Pharma Q1 FY27 consolidated revenue Rs 15,299.90 cr, PAT Rs 2,894.80 cr
For Q1 FY27, Sun Pharma reported consolidated revenue from operations of Rs 15,299.90 cr and net profit of Rs 2,894.80 cr, up from Rs 13,851.40 cr and Rs 2,278.60 cr in Q1 FY26.
Key takeaways
- Revenue from operations Rs 15,299.90 cr in Q1 FY27 vs Rs 13,851.40 cr in Q1 FY26.
- Gross Profit Rs 12,220.40 cr in Q1 FY27 vs Rs 10,178.40 cr in Q1 FY26.
- EBITDA Rs 4,417.70 cr in Q1 FY27 vs Rs 4,301.70 cr in Q1 FY26.
- Net Profit Rs 2,894.80 cr in Q1 FY27 vs Rs 2,278.60 cr in Q1 FY26.
- EPS (Diluted) INR 12.1 in Q1 FY27 vs INR 9.5 in Q1 FY26.
Q1 FY27 · consolidated
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | Rs 15,299.90 cr | Rs 13,851.40 cr | +10.5% |
| PAT | Rs 2,894.80 cr | Rs 2,278.60 cr | +27.0% |
| EPS | INR 12.1 | INR 9.5 | +27.0% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
-
Net margin was 18.92% of revenue, up 247 bps from 16.45%.
-
Basis & period: Consolidated results for Q1 FY27 (quarter ended 30 June 2026), compared with Q1 FY26 (quarter ended 30 June 2025), as per the Key Financials Q1 FY27 table.
-
Revenue from operations: Rs 15,299.90 cr in Q1 FY27 vs Rs 13,851.40 cr in Q1 FY26.
-
Gross Sales: Rs 15,183.60 cr in Q1 FY27 vs Rs 13,786.10 cr in Q1 FY26.
-
Gross Profit: Rs 12,220.40 cr in Q1 FY27 vs Rs 10,178.40 cr in Q1 FY26.
-
EBITDA: Rs 4,417.70 cr in Q1 FY27 vs Rs 4,301.70 cr in Q1 FY26.
-
Net Profit: Rs 2,894.80 cr in Q1 FY27 vs Rs 2,278.60 cr in Q1 FY26.
-
Net Profit (Adjusted): Rs 3,089.40 cr in Q1 FY27 vs Rs 2,996.10 cr in Q1 FY26.
-
R&D: Rs 826.40 cr in Q1 FY27 vs Rs 902.90 cr in Q1 FY26.
-
EPS (Diluted): INR 12.1 in Q1 FY27 vs INR 9.5 in Q1 FY26.
-
EPS (Diluted) (Adjusted): INR 12.9 in Q1 FY27 vs INR 12.5 in Q1 FY26.
According to the Key Financials Q1 FY27 section of the investor presentation, consolidated revenue from operations for Q1 FY27 stood at Rs 15,299.90 cr, compared with Rs 13,851.40 cr in Q1 FY26. Gross Sales for the quarter were Rs 15,183.60 cr against Rs 13,786.10 cr a year earlier. Gross Profit increased to Rs 12,220.40 cr in Q1 FY27 from Rs 10,178.40 cr in Q1 FY26.
EBITDA for Q1 FY27 was Rs 4,417.70 cr, slightly higher than Rs 4,301.70 cr in the corresponding quarter of the previous year. Net Profit rose to Rs 2,894.80 cr in Q1 FY27 from Rs 2,278.60 cr in Q1 FY26. On an adjusted basis, Net Profit was Rs 3,089.40 cr in Q1 FY27 versus Rs 2,996.10 cr in Q1 FY26, with the presentation separately detailing the adjustments applied to each period.
R&D spend for the quarter was Rs 826.40 cr, compared with Rs 902.90 cr in Q1 FY26. Diluted EPS for Q1 FY27 was reported at INR 12.1, up from INR 9.5 in Q1 FY26. Adjusted diluted EPS was INR 12.9 in Q1 FY27 versus INR 12.5 in Q1 FY26, as per the same table in the investor presentation.
Track Sun Pharmaceutical Industries Ltd
Cruxal reads every Sun Pharmaceutical Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
